导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.58% | 3526/4773 |
| 近一周 | -1.05% | 307/5462 |
| 近一月 | 2.39% | 275/5421 |
| 近一季 | 1.28% | 558/5209 |
| 近半年 | -1.31% | 1548/4920 |
| 近一年 | -5.49% | 3150/4366 |
| 近两年 | 32.67% | 2172/2954 |
| 近三年 | 24.14% | 1317/2253 |
| 成立以来 | 26.24% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.50% 4297/4961 |
-3.84% 3477/5312 |
- - |
- - |
| 2025 | 9.91% 2844/4813 |
-1.66% 2733/3635 |
8.43% 335/4076 |
-0.32% 3923/4524 |
3.40% 680/4813 |
| 2024 | 32.11% 87/3463 |
2.36% 791/2808 |
0.54% 583/3014 |
26.39% 265/3129 |
1.56% 1052/3463 |
| 2023 | -4.68% 690/2656 |
-1.05% 1849/2280 |
-0.30% 374/2385 |
5.00% 106/2515 |
-7.98% 2227/2655 |
| 2022 | -11.95% 265/2207 |
-5.10% 178/1919 |
-1.43% 1722/2016 |
-10.34% 384/2113 |
4.98% 497/2208 |
| 2021 | -7.15% 1030/1822 |
-1.51% 505/1255 |
-2.28% 1197/1330 |
-4.16% 683/1466 |
0.66% 1081/1822 |
| 2020 | 2.12% 926/1250 |
-14.21% 953/1028 |
5.07% 891/1067 |
9.09% 674/1164 |
3.85% 887/1184 |
| 2019 | 34.60% 396/1092 |
26.76% 379/739 |
-0.70% 275/788 |
-0.67% 605/850 |
7.65% 414/918 |
| 2018 | -18.28% 141/834 |
- - |
-11.95% 374/631 |
5.76% 56/660 |
-7.82% 73/682 |
| 2017 | 19.46% 193/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.10% 255/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发中证全指金融地产联接A VS. 长安沪深300非周期A(740101) |